Although studies of clinical meaningfulness in the context of DMTs have investigated the ADLs, CDR‐SB, and time savings to clinically meaningful outcomes, 10 , 18 , 19 , 20 we sought an approach that would facilitate discussions between patients and providers regarding DMTs and how they may impact time to needing higher levels of care. This study aimed to connect a key outcome measure used by clinical trials (CDR‐SB) to outcomes that are more likely to be meaningful to patients and their families (independence in ADLs). More specifically, we estimated the number of months treatment with anti‐amyloid monoclonal antibodies would be expected to prolong independence.
